Cost-effectiveness of bronchial thermoplasty for severe asthmatic patients in Japan

Shuichiro Matsumoto,Motoyasu Iikura,Yusaku Kusaba,Takashi Katsuno,Yoshie Tsujimoto,Tamaki Kakuwa,Sachi Matsubayashi,Naoko Nagano,Keita Sakamoto,Masao Hashimoto,Satoru Ishii,Manabu Suzuki,Go Naka,Shinyu Izumi,Yuichiro Takeda,Masayuki Hojo,Haruhito Sugiyama
DOI: https://doi.org/10.35772/ghm.2020.01067
2020-12-31
Abstract:Bronchial thermoplasty (BT) is an interventional endoscopic treatment for severe bronchial asthma. Some studies have shown the clinical efficacy of this intervention, but its cost-effectiveness is unclear. The aim of this study was to evaluate the cost-effectiveness of BT. We collected data from the medical records of 16 Japanese patients who were treated with BT between February 2015 and April 2017, and compared asthma-related medical expenses between the year preceding and the year following BT. Four patients were Global Initiative for Asthma (GINA) treatment step 4, and 12 were step 5. In 8 patients who had a successful response to BT, the annual asthma-related medical expenses decreased because of a reduction in hospitalization and emergency outpatient visits due to asthma attacks, and termination of the use of biologics. Most patients in the non-responder group had increased asthma-related medical costs postoperatively. The main reason for the increase in medical costs was the add-on treatment of biologics. BT was cost-effective in the responder group. If its effects continue for more than 10 years, BT will be a cost-effective treatment. Medical costs will be reduced if those who respond to BT can be identified prior to commencement of treatment.
What problem does this paper attempt to address?